May 15, 2018
Biophytis receives Orphan Drug Designation from the FDA for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
Biophytis receives Orphan Drug Designation from the FDA for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
BIOPHYTIS updates on clinical development of Macuneos and presents its effects on visual function in a preclinical model of AMD at 2018 ARVO Congress. Read the Press Release
2017 Annual Financial Report made available. Read the Press Release
Interview of Stanislas Veillet, CEO of Biophytis for the European Smallcap event 2018 with Didier Testot, journalist on the Web tv www.labourseetlavie.com
Biophytis files for Orphan Drug Designation for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami. Read the Press Release
Biophytis to participate in upcoming sectorial events over the first half of 2018. Read the Press Release
Biophytis to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018. Read the Press Release
Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD). Read the Press Release